# US 2012/0252905 A1 · Drug delivery from rapid gelling polymer composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252905 A1
- Document ID: US20120252905A1
- Status: Published application
- Kind: A1
- Application number: 13/461,424
- Filed: 2012-05-01
- Published: 2012-10-04
- Earliest claimed: 2002-12-30
- Assignees: Angiotech International AG
- Inventors: David M. Gravett; Aniko Takacs-Cox; Philip M. Toleikis; Arpita Maiti; Leanne Embree
- Web page: https://patentgrep.com/patent/US20120252905A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/365: Lactones
- A61K 31/54: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 31/041: {Mixtures of macromolecular compounds}
- A61L 31/145: {Hydrogels or hydrocolloids}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 47/6903: {the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel}
- A61K 51/1213: {Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature}
- A61L 2300/434: of enzymes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.

## Claims

### Claim at position 1

1-126. (canceled)

### Claim 127

A drug-delivery system comprising:
a first component comprising a sulfhydryl group-containing compound of formula: Compound1-(SH)m wherein m≧2; and
a second component comprising a sulfhydryl reactive group-containing compound of formula: Compound2-Yn, wherein Y is a sulfhydryl reactive group and wherein n≧2; and
a hydrophobic drug,
wherein, when the first component contacts the second component in a liquid medium, Compound1-(SH)m and Compound2-Yn form covalent bonds between the sulfhydryl groups and Y to form a biocompatible gel in less than one minute, and wherein the hydrophobic drug is admixed in the biocompatible gel.

### Claim 128 (depends on 127)

The drug-delivery system of claim 127, wherein m and n are each 4 or 12.

### Claim 129 (depends on 127)

The drug-delivery system of claim 127, wherein Compound1 and Compound2 are each a polyalkylene oxide.

### Claim 130 (depends on 129)

The drug-delivery system of claim 129, wherein the polyalkylene oxide is polyethylene glycol.

### Claim 131 (depends on 127)

The drug-delivery system of claim 127, wherein Y is succinimidyl ester or maleimidyl.

### Claim 132 (depends on 127)

The drug-delivery system of claim 127 wherein the first component is in a first container and the second component is in a second container.

### Claim 133 (depends on 132)

The drug-delivery system of claim 132 wherein the first component is in a in a liquid medium having an alkaline pH and the second component is in either a liquid medium having a neutral or acidic pH or in powder form.

### Claim 134 (depends on 127)

The drug-delivery system of claim 127 wherein the first component and the second component are a mixture of powders in a first container, and the drug-delivery system further comprises an acidic buffer solution in a second container.

### Claim 135 (depends on 134)

The drug-delivery system of claim 134 further comprises an alkaline buffer solution.

### Claim 136 (depends on 127)

The drug-delivery system of claim 127 wherein the hydrophobic drug is a cell cycle inhibitor or an analogue or derivative thereof.

### Claim 137

A method for forming a drug-loaded biocompatible gel in situ, comprising:
providing a first component comprising a sulfhydryl group-containing compound of formula: Compound1-(SH)m in a liquid medium having an alkaline pH, wherein m≧2;
providing a second component comprising a sulfhydryl reactive group-containing compound of formula: Compound2-Yn in either a liquid medium having a neutral or acidic pH or in powder form, wherein Y is a sulfhydryl reactive group and wherein n≧2;
combining a hydrophobic drug with either the first component or the second component; and
combining the first component and the second component to form a gel incorporating the hydrophobic drug, wherein the sulfhydryl groups and the sulfhydryl reactive groups react with one another to form covalent bonds therebetween.

### Claim 138 (depends on 137)

The method of claim 137, wherein m and n are each 4 or 12.

### Claim 139 (depends on 137)

The method of claim 137, wherein Compound1 and Compound2 are each a polyalkylene oxide.

### Claim 140 (depends on 137)

The method of claim 137, wherein Y is succinimidyl ester or maleimidyl.

### Claim 141 (depends on 137)

The method of claim 137 wherein the hydrophobic drug is a cell cycle inhibitor or an analogue or derivative thereof.

### Claim 142

A method for forming a drug-loaded biocompatible gel in situ, comprising:
providing a powdered mixture of a sulfhydryl group-containing compound of formula: Compound1-(SH)m wherein m≧2, a sulfhydryl reactive group-containing compound of formula: Compound2-Yn, wherein Y is a sulfhydryl reactive group and wherein n≧2, and a hydrophobic drug;
providing a first buffer having an acidic pH;
providing a second buffer having an alkaline pH;
combining the powdered mixture with the first buffer to obtain a solution;
combining the solution of the powdered mixture with the second buffer form a gel incorporating the hydrophobic drug, wherein the sulfhydryl groups and the sulfhydryl reactive groups react with one another to form covalent bonds therebetween.

### Claim 143 (depends on 142)

The method of claim 142, wherein m and n are each 4 or 12.

### Claim 144 (depends on 142)

The method of claim 142, wherein Compound1 and Compound2 are each a polyalkylene oxide.

### Claim 145 (depends on 142)

The method of claim 142, wherein Y is succinimidyl ester or maleimidyl.

### Claim 146 (depends on 142)

The method of claim 142, wherein the hydrophobic drug is a cell cycle inhibitor or an analogue or derivative thereof.
